Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Net Cash Flow history spans 8 years, with the latest figure at -$16.4 million for Q1 2026.

  • Quarterly Net Cash Flow fell 129.98% to -$16.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$40.1 million through Mar 2026, up 3.47% year-over-year, with the annual reading at $31.0 million for FY2025, 139.2% up from the prior year.
  • Net Cash Flow came in at -$16.4 million for Q1 2026, down from $18.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $82.5 million in Q2 2024 to a low of -$508.1 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$10.4 million (2025), against an average of -$40.3 million.
  • Year-over-year, Net Cash Flow plummeted 2271.42% in 2022 and then surged 428.28% in 2024.
  • Atea Pharmaceuticals' Net Cash Flow stood at $11.9 million in 2022, then plummeted by 50.29% to $5.9 million in 2023, then plummeted by 668.76% to -$33.8 million in 2024, then skyrocketed by 154.4% to $18.4 million in 2025, then crashed by 189.26% to -$16.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Net Cash Flow are -$16.4 million (Q1 2026), $18.4 million (Q4 2025), and -$10.4 million (Q3 2025).